Novavax Announces Board of Director Changes

Novavax Announces Board of Director Changes

ROCKVILLE, Md., Oct. 1 /PRNewswire-FirstCall/ -- novavax, Inc. (Nasdaq: NVAX) announced today that Stanley Erck has been appointed to the board's corporate governance, compensation and finance committees, replacing board chairman John Lambert on the finance committee and board member James Tananbaum who is retiring from the board. Mr. Erck has previously served as CEO of several vaccine and immunology products companies and joined the novavax board in June 2009.

John Lambert stated: "Our board's membership and responsibilities are continuing to evolve as novavax matures as an operating company and advances its vaccine candidates toward commercialization. We thank Jim for his three and a half years of service to our company and appreciate Stan's willingness to take on additional responsibilities which reflect his experience in vaccine development and the biopharmaceutical industry."

Dr. Tananbaum commented: "I have greatly enjoyed my affiliation with novavax and am impressed with the company's recent progress. VLP technology is proving to be a valuable platform for vaccine development and I wish the team continued success in the years ahead."

About novavax

Novavax is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches.

Forward Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.